M E Blair Holbein

  • 233 Citations
  • 7 h-Index
1983 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where M E Blair Holbein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

United States Food and Drug Administration Medicine & Life Sciences
Research Personnel Medicine & Life Sciences
Investigational Drugs Medicine & Life Sciences
Investigational New Drug Application Medicine & Life Sciences
Vitamin E Medicine & Life Sciences
Endotoxins Medicine & Life Sciences
Cost-Benefit Analysis Medicine & Life Sciences
Retinopathy of Prematurity Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1983 2019

  • 233 Citations
  • 7 h-Index
  • 14 Article
  • 1 Chapter
  • 1 Letter

Count me in: using a patient portal to minimize implicit bias in clinical research recruitment

Kannan, V., Wilkinson, K. E., Varghese, M., Lynch-Medick, S., Willett, D. L., Bosler, T. A., Chu, L., Gates, S. I., Holbein, M. E. B., Willett, M. M., Reimold, S. C. & Toto, R. D., Aug 1 2019, In : Journal of the American Medical Informatics Association : JAMIA. 26, 8-9, p. 703-713 11 p.

Research output: Contribution to journalArticle

Open Access
Registries
Research
Demography
Hispanic Americans
Chronic Disease
15 Citations (Scopus)

Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?

Holbein, M. E. B., Berglund, J. P., Weatherwax, K., Gerber, D. E. & Adamo, J. E., Oct 1 2015, In : Clinical and Translational Science. 8, 5, p. 526-532 7 p.

Research output: Contribution to journalArticle

Investigational Drugs
Legislation
Biological Factors
Pharmaceutical Preparations
Research Ethics Committees
1 Citation (Scopus)

Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award consortium: Developing and implementing a sponsor-investigators training program

Holbein, M. E. B., Berglund, J. P., O'Reilly, E. K., Hartman, K., Speicher, L. A., Adamo, J. E., O'Riordan, G., Brown, J. S. & Schuff, K. G., 2014, In : Journal of Investigative Medicine. 62, 5, p. 797-803 7 p.

Research output: Contribution to journalArticle

Investigational Drugs
Advisory Committees
Research Personnel
Education
Equipment and Supplies

Warning letters to sponsor- investigators at academic health centres - the regulatory "canaries in a coal mine"

O'Reilly, E. K., Holbein, M. E. B., Berglund, J. P., Parrish, A. B., Roth, M. T. & Burnett, B. K., 2013, In : Clinical and Investigative Medicine. 36, 6

Research output: Contribution to journalArticle

Canaries
Coal
United States Food and Drug Administration
Research Personnel
Health

Understanding food and drug administration (FDA) regulatory requirements for investigational new drug applications (IND) for sponsor-investigators

Holbein, M. E. B., Jan 1 2012, Clinical Research: From Proposal to Implementation. Wolters Kluwer Health Adis (ESP), p. 132-146 15 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Investigational New Drug Application
United States Food and Drug Administration
Research Personnel